Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Berger

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Neoplasia (New York, N.Y.)|November 3, 2021
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosisDaniela Berger, Karin Bauer, Christoph Kornauth, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Ebiomedicine|November 26, 2019
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1<sup>T315I</sup>+ clones in TKI-resistant CMLMathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, et al.
Leukemia|March 31, 2021
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemiaGregor Eisenwort, Irina Sadovnik, Alexandra Keller, et al.
Blood|July 19, 2018
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosisNiklas Mueller, Daniel Wicklein, Gregor Eisenwort, et al.
Cancers|July 9, 2022
CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in <i>KIT</i> D816V<sup>+</sup> Neoplastic Mast CellsMathias Schneeweiss-Gleixner, Yüksel Filik, Gabriele Stefanzl, et al.
American Journal of Hematology|July 7, 2022
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph<sup>+</sup> chronic myeloid leukemiaBarbara Peter, Gregor Eisenwort, Irina Sadovnik, et al.
Haematologica|February 14, 2018
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosisMathias Schneeweiss, Barbara Peter, Siham Bibi, et al.
Neoplasia (New York, N.Y.)|May 18, 2018
Phenotyping and Target Expression Profiling of CD34<sup>+</sup>/CD38<sup>-</sup> and CD34<sup>+</sup>/CD38<sup>+</sup> Stem- and Progenitor cells in Acute Lymphoblastic LeukemiaKatharina Blatt, Ingeborg Menzl, Gregor Eisenwort, et al.
Journal of Immunological Methods|May 2, 2021
Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a sourceJessy Elst, Didier G Ebo, Margaretha A Faber, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Neoplasia (New York, N.Y.)|November 3, 2021
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosisDaniela Berger, Karin Bauer, Christoph Kornauth, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Ebiomedicine|November 26, 2019
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1<sup>T315I</sup>+ clones in TKI-resistant CMLMathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, et al.
Leukemia|March 31, 2021
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemiaGregor Eisenwort, Irina Sadovnik, Alexandra Keller, et al.
Blood|July 19, 2018
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosisNiklas Mueller, Daniel Wicklein, Gregor Eisenwort, et al.
Cancers|July 9, 2022
CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in <i>KIT</i> D816V<sup>+</sup> Neoplastic Mast CellsMathias Schneeweiss-Gleixner, Yüksel Filik, Gabriele Stefanzl, et al.
American Journal of Hematology|July 7, 2022
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph<sup>+</sup> chronic myeloid leukemiaBarbara Peter, Gregor Eisenwort, Irina Sadovnik, et al.
Haematologica|February 14, 2018
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosisMathias Schneeweiss, Barbara Peter, Siham Bibi, et al.
Neoplasia (New York, N.Y.)|May 18, 2018
Phenotyping and Target Expression Profiling of CD34<sup>+</sup>/CD38<sup>-</sup> and CD34<sup>+</sup>/CD38<sup>+</sup> Stem- and Progenitor cells in Acute Lymphoblastic LeukemiaKatharina Blatt, Ingeborg Menzl, Gregor Eisenwort, et al.
Journal of Immunological Methods|May 2, 2021
Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a sourceJessy Elst, Didier G Ebo, Margaretha A Faber, et al.
Pageof 6